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Introduction
During the first half of the last century, the management 
of hypertension was regarded with concern, 
and several authors considered the treatment of 
hypertension as potentially dangerous, particularly 
among older people. Much of this concern was 
related to the paucity of information on the disease, 
and the almost total lack of suitable pharmacological 
agents for blood pressure control. Today, the situation 
is very different, where failure to treat any form of 
hypertension is regarded as potentially poor medicine, 
and possibly even indefensible practice.
Background
Hypertension is extremely common, affecting over 
one billion people worldwide, and is responsible for 
over seven million deaths annually. The presence of 
hypertension increases the risk of myocardial infarction, 
heart failure, renal failure and stroke, and is associated 
with an ageing population, since older people are 
more likely to suffer from systolic hypertension. As this 
patient group is also more likely to require surgery, the 
management of hypertension poses considerable 
challenges to anaesthetic practitioners.
Hypertension is not a disease entity in itself, but a 
diagnosis that incorporates a range of diseases. 
Most hypertension is referred to as “essential 
hypertension”, implying that the underlying cause 
of the condition is unknown. This categorisation 
encompasses approximately 95% of all hypertensive 
patients, although increasing the understanding of 
the underlying medical conditions will allow better 
diagnosis of other causative conditions. The remaining 
five per cent of hypertension is “secondary”, in which 
the underlying cause of the high blood pressure is a 
known medical condition. These can be categorised 
into vascular pathology, such as coarctation of the 
aorta or renal artery stenosis, endocrine conditions, 
particularly phaeochromocytoma, Cushing’s syndrome 
and primary hyperaldosteronism, renal disease, 
obstetric causes, and misuse of drugs for either clinical 
or recreational purposes. Secondary hypertension 
must always be considered in young patients with 
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Abstract
Hypertension is common among patients presenting for surgery, and is frequently untreated or inadequately 
treated. While the approach to the patient with hypertension presenting for anaesthesia is controversial, and the 
evidence base for appropriate clinical decisions is weak, this is a problem that practising clinical anaesthetists 
face on a regular basis. This article seeks to present a unified approach to the problem of a hypertensive patient 
presenting for surgery, and offers suggestions as to the appropriate management options. As far as possible, the 
recommendations contained in this article have been based on the best available evidence.
The authors suggest that moderate degrees of hypertension (up to 180/120 mmHg), without obvious target organ 
disease, should never be grounds for postponing surgery. Even with greater degrees of hypertension, the relative 
risk of postponing surgery should always be considered. There is little evidence that, in patients without target organ 
disease, delaying surgery in order to establish antihypertensive therapy is beneficial. For very severe hypertension, 
the benefits of delaying surgery to establish adequate hypertensive control must be weighed against the risk of 
delayed surgery. Where a surgical delay is considered, adequate time to establish appropriate blood pressure 
control must be allowed, and there is no place for sudden “cosmetic” correction of blood pressure immediately 
prior to anaesthesia. Previously undiagnosed hypertension, presenting for the first time at surgery, requires a basic 
investigation of target organ disease prior to anaesthesia, and appropriate subsequent follow-up referral for further 
management.
Reprinted with permission from S Afr J Anaesth Analg 2011;17(2):168-173
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severe hypertension, in any patient with resistant 
hypertension, or in patients with atypical presentations, 
as the consequences of a failure of diagnosis may 
be catastrophic, especially in the perioperative 
period. However, these conditions represent specific 
management problems, and will not be considered 
further here. Recently, endocrine causes have been 
extensively reviewed.1
Definitions and classification
The severity of hypertension is categorised into fairly 
well- defined and accepted bands, as is illustrated in 
Table I (the classification is modified from Aronson et al 
and Dix P).2,3 It is most important to appreciate that the 
classification of hypertension is based on the average 
of two or more stable readings of arterial pressure, 
taken at two or more visits after initial screening, 
and not on a single isolated recording. However, it is 
increasingly recognised that office, or in- hospital 
pressure recording is the least reliable assessment 
of blood pressure, and that validated home blood 
pressure monitors are better equipped to assess blood 
pressure control as they avoid the problems of “white 
coating”.
Table I: Classification of hypertension (all values are in mmHg)






Optimal < 120 and < 80
Normal < 130 and < 85
High normal 130-139 or 85-89
Hypertension
Stage 1: Mild 140-159 or 90-99
Stage 2: Moderate 160-179 or 100-109
Stage 3: Severe 180-209 or 110-119
Stage 4: Very severe > 210 or > 120
Isolated systolic 
hypertension > 140 and < 90
Pulse pressure 
hypertension > 80
Note: The South African Hypertension Society only recognises up to Stage 3,4 but the 
other grades are useful for perioperative decisions.
Pathogenesis
Systolic blood pressure (SBP) rises continuously with 
age, while diastolic blood pressure (DBP) reaches a 
plateau in the fifth or sixth decade, and may then 
decrease.5 Thus, systolic hypertension is more common 
in the elderly, and consequently an increase in pulse 
pressure is seen in older patients. Whereas it used to 
be thought that DBP is the most important determinant 
of outcome and the prime target for blood pressure 
control, current thinking is that systolic pressure 
hypertension, where the pulse pressure exceeds 
65 mmHg, is the crucial issue. Consequently, systolic 
hypertension is now regarded as the principal target 
for blood pressure control in older patients.5 There 
is increasing emphasis on the importance of pulse 
pressure hypertension, which is now being recognised 
as imposing a significant risk of myocardial infarction 
and stroke. The incidence of a raised pulse pressure 
increases with age, and is also found more commonly 
in patients with the metabolic syndrome, as well as 
in patients with coronary artery disease. The pulsatile 
stress on the vasculature is increased, and this leads 
to increased risk of plaque rupture, left ventricular 
hypertrophy and renal failure. This haemodynamic 
abnormality contributes to endothelial dysfunction, 
as well as an increase in pulsatile load. This may be 
particularly true in the elderly population requiring 
surgery, and in anaesthetic management.2 A rise 
in pulse pressure in the first trimester of pregnancy is 
a marker for the development of pre-eclampsia. 
Hypertension of all types increases the risk of 
mortality, with severe hypertension (SBP greater than 
180 mmHg) increasing the relative risk of death sixfold.6 
Of importance here is that low diastolic pressure may 
limit myocardial perfusion, which occurs in diastole.
End-organ damage, predominantly of the heart, the 
kidney and brain, is common in hypertension. Even 
asymptomatic hypertension presents a risk of end-
organ damage, and as the disease advances, renal 
injury may progress to end-stage renal failure. The heart 
will suffer from hypertrophy, coronary artery disease, 
and systolic and diastolic dysfunction, all ultimately 
increasing the risk of myocardial infarction, cardiac 
failure and death. The brain is also at substantial 
risk, with hypertension increasing the incidence of 
dementia and ischaemic or haemorrhagic cerebral 
events, leading to stroke.
In the heart, a vicious cycle is established by the 
increased myocardial oxygen demand caused by 
increased myocardial wall tension, which is amplified 
by left ventricular hypertrophy. Both of these changes 
lead to coronary insufficiency, infarction and heart 
failure. Concentric hypertrophy leads to increasing 
ventricular muscle thickness, but a relative reduction in 
cardiac chamber size, and an increase in ischaemic 
risk. The ratio of blood vessel cross-sectional area to left 
ventricular mass becomes progressively less favourable, 
meaning that cardiac oxygen supply is jeopardised.7 
Subendocardial autoregulation is also impaired, 
leading to diminished tolerance of unstable blood 
pressure. Diastolic dysfunction is seen increasingly 
frequently with advancing age, occurring in up to 
70% of patients with heart failure. It is associated with 
severe, long- standing hypertension and is frequently 
seen in patients with catecholamine excess.8
Loss of autoregulation predisposes the kidney to 
damage from hypotensive events, and there is an 
increasing incidence of glomerular sclerosis, and a 
reduction in glomerular filtration rate, with advancing 
hypertension. Pulse pressure hypertension significantly 
increases the risk of postoperative renal failure.9
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The shift of autoregulatory thresholds in the brain 
in hypertensives is well known, and hypertension 
increases the perioperative risk of both ischaemic 
and haemorrhagic strokes. Carotid stenosis is more 
common in hypertensive patients, adding to the 
ischaemic risk. Pulse pressure hypertension increases 
the risk of adverse cardiac and cerebral events, 
following coronary artery bypass surgery.10
Treatment
There is no doubt that treatment of hypertension 
has a marked effect on complications, reducing 
the incidence of stroke and cardiac failure, and 
substantially improving five-year morbidity and 
mortality. A variety of drugs have been used to 
manage hypertension, of which the thiazide diuretics 
have the longest and best established track record in 
improving outcome. This is partly because these drugs 
have been the most widely used agents, but they 
should also always be the first-line treatment of choice 
in essential hypertension. Beta blockade is widely 
used in the treatment of severe hypertension, with the 
probability of beta-blockade administration increasing 
with the severity of the disease and its complications.11 
However, no one drug is superior to another in the 
treatment of hypertension, although beta blockers 
are associated with reduced stroke protection, and 
calcium-channel blockers (CCBs) with slightly better 
stroke protection, according to a recent meta-
analysis.12 Five major classes of drugs are recognised 
for the treatment of essential hypertension [diuretics, 
angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin-receptor blockers (ARBs), CCBs and beta 
blockers]. The choice of agent depends on conditions 
that favour, or relatively or absolutely contraindicate 
the use of individual drugs, for example beta blockers 
for patients with ischaemic heart disease (IHD). 
Increasing trial evidence suggests that an ACE inhibitor 
plus a CCB, offer better cardiovascular protection than 
an ACE inhibitor plus a diuretic, or a diuretic plus a beta 
blocker.13 The range of drugs widely used for chronic 
treatment of hypertension is shown in Table II.
Perioperative risk
For a long time, the contribution of hypertension to 
anaesthetic risk has been controversial. Early studies 
suggested that hypertension presented a major hazard 
for anaesthesia, and a number of studies in the 1960s 
and 1970s seemed to confirm this. However, both 
contemporaneous and later studies failed to support 
the concept that hypertension alone was a major 
anaesthetic risk factor.14 A meta-analysis from the 
Oxford group showed a small, but significant increase 
in the risk of perioperative complications in association 
with hypertension (OR 1.3, 95% CI 1.17-1.56), but the 
studies are very heterogeneous, particularly regarding 
the nature of the perioperative complications 
recorded, and the likelihood of risk.6 Certainly, the 
current weight of evidence suggests that hypertension 
alone carries minimal anaesthetic risk.15 
An important issue, particularly related to the question 
regarding the postponement of surgery in hypertensive 
patients, is whether or not treating hypertension 
alters anaesthetic risk. One study, in particular, had a 
profound effect on this debate. In this very small study, 
untreated hypertensives showed a markedly higher 
rate of arrhythmia development during anaesthesia, 
and of postoperative myocardial ischaemia.16 The 
untreated and treated hypertensives both had similar 
resting arterial pressures, but the untreated group 
demonstrated greater fluctuations in arterial pressure, 
which possibly accounted for the adverse cardiac 
events. However, a subsequent much larger study 
failed to confirm this observation, finding similar risks 
for perioperative myocardial events in untreated, 
well-treated or poorly treated hypertensive patients.17 
Another small study found much greater increases in 
blood pressure following tracheal intubation in patients 
who were found to have labile blood pressures, with a 
higher incidence of myocardial ischaemia in this group.18 
In patients undergoing carotid endarterectomy, 
poorly controlled hypertension predicted transient 
neurological deficits in the postoperative period, but 
this difference disappeared after 24 hours.19 Perhaps 
more importantly, a major retrospective study by the 
Oxford group demonstrated that hypertension resistant 
to treatment was a major predictor for perioperative 
silent myocardial ischaemia.20 It seems, on balance, 
that established treatment of hypertension with a 
good response may reduce the perioperative risks 
of hypertension, and that resistant hypertension may 
represent a higher risk group, but at present, data are 
inadequate to make this a definitive conclusion.
Hypertension is most certainly associated with increased 
haemodynamic instability in the perioperative period, 
and this is associated with an increased risk of myocardial 
injury. Furthermore, hypertension is a major risk factor 
for coronary artery disease, congestive cardiac 
failure, and renal and cerebral disease, all of which 
increase the perioperative risk. Hypertension is also 
associated with dyslipidaemia, diabetes and obesity, 
Table II: Long-term management drugs






Beta blockers Atenolol, bisoprolol, 
carvedilol, esmolol
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and the side-effects of the drugs required to treat 
these conditions. Hypertension is therefore associated 
with an increased risk of end-organ disease, which 
would certainly increase perioperative risk. However, it 
remains unclear whether uncomplicated hypertension 
is a perioperative risk factor, and probably on its own, it 
is insufficient justification to cancel surgery.21
Perioperative approaches
As is clear from the above information, careful 
preoperative evaluation of the hypertensive patient 
is important. Such an evaluation should include a 
review of the quality of blood pressure control, and 
the antihypertensive agents needed to achieve that 
condition. It is perhaps more important to detect 
end-organ dysfunction that may have resulted from 
hypertension, as this is much more likely to predict 
perioperative adverse events than the hypertension 
alone. Such end-organ damage includes cardiac 
injury, cerebral vascular disease, renal dysfunction 
and peripheral vascular disease, all of which are 
independent risk factors for perioperative adverse 
events. All patients found to have preoperative 
hypertension require appropriate investigation. This 
should include a preoperative electrocardiogram 
(ECG), blood sugar analysis, electrolytes and creatinine 
measurement [with calculation of glomerular 
filtrationrate (GFR)], together with a urinary dipstick. 
Where the situation is urgent, these investigations must 
be performed, even if only postoperatively.
Therefore, a decision as to when to delay surgery in a 
patient with hypertension must consider the risk-benefit 
ratio of such a delay. It seems unlikely that significant 
benefit will be gained in an otherwise uncomplicated 
hypertensive patient, even with Stage 3 hypertension 
or higher, unless the surgery can be safely delayed 
for the two to three months that will be required to 
produce significant changes in cardiovascular and 
arterial morphology.
There is evidence in hypertension studies that in high-
risk patients,benefits from cardiovascular protection 
are seen within three months,22 and in some aggressive 
statin studies, there is evidence of benefit that may be 
seen within 30 days.23 The decision to delay elective 
surgery in hypertensives should be based on risk, in other 
words blood pressure > 180/110nmHg (always high 
risk), evidence of target organ damage or subclinical 
organ dysfunction, and/or multiple risk factors such as 
diabetes, smoking and resting ischaemia on the ECG. 
Subclinical organ damage is indicated by proteinuria, 
estimated GFR < 60 ml/minute and ECG evidence of 
left ventricular hypertrophy. In such patients, surgery 
should be deferred for at least four to six weeks and 
all risk factors (arterial pressure, smoking, elevated 
cholesterol and diabetes) should be controlled 
aggressively. Sudden normalisation of arterial pressure 
over a few days immediately prior to surgery is not 
recommended.
All emergency surgery should proceed regardless of 
the level of blood pressure, and urgent surgery should 
also not be delayed for uncomplicated hypertension. 
However, there is some evidence that benefit may be 
gained from treating severe hypertension, particularly 
severe pulse pressure hypertension (> 80 mmHg) or 
severe diastolic hypertension, especially in younger 
patients requiring elective surgery. Other patients, in 
whom a delay in elective surgery may be warranted, 
include those with treatable end-organ disease risk, 
and those experiencing complications of therapy, 
particularly related to renal, cardiac or cerebral 
vascular events. The American College of Cardiology 
(ACC)/ American Heart Association (AHA) guidelines 
suggest that a systolic arterial pressure greater than 
180 mmHg, and/ or a diastolic arterial pressure greater 
than 110 mmHg, is justification for the establishment of 
control of hypertension prior to surgery. Furthermore, 
these guidelines state that the use of rapid-acting 
agents to control blood pressure in the hours prior to 
surgery may be considered, but advance no evidence 
for this view.24 This practice may, in fact, be dangerous 
in patients who have lost cerebral, renal or cardiac 
autoregulation.
This recommendation may be completely inappropriate 
when applied to acute beta blockade in light of 
the subsequently published Perioperative Ischemic 
Evaluation Study (POISE). In this study, beta blockade 
was given acutely to at-risk patients two to four hours 
prior to major non-cardiac surgery. Although there 
was a reduction in the rate of myocardial infarction, 
all-cause mortality, particularly from stroke, was 
increased.25 Immediate preoperative beta blockade 
should therefore be used with caution.26 The addition 
of a statin is probably justified in any patient with a high 
risk of myocardial injury.27 In high-risk patients, acute 
hypotension is more dangerous than modest elevations 
in blood pressure. Where urgent surgery is required in a 
patient with Stage 4 hypertension, it may be helpful to 
attempt to decrease arterial pressure with vasodilator 
agents by approximately 25%, prior to induction of 
anaesthesia. Shortacting agents such as nitroprusside 
or glyceryl trinitrate may be helpful, as they can be 
discontinued rapidly should hypotension become 
a problem, but there is no conclusive evidence to 
support this practice.
At present, the overwhelming evidence is that patients 
with mild-to-moderate hypertension (see Table I) 
without subclinical organ dysfunction, or additional 
risk factors, should proceed to anaesthesia and 
surgery without delay.6 An isolated recording of a 
very high blood pressure immediately prior to surgery 
is not necessarily a reason to postpone the surgery. 
In such cases, where prior information is available, 
such as ward blood pressures, or information from the 
patient’s family practitioner that suggests that the 
resting arterial pressure is well controlled, it may be 
reasonable to proceed with anaesthesia, but there is 
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no evidence for or against this position. However, such 
an episode identifies a patient as a potentially unstable 
hypertensive. There is growing evidence that such 
patients deserve increased medical surveillance.28 For 
poorly controlled, severe hypertension patients (Stage 
3) who are scheduled for elective surgery. It is probably 
justified to delay surgery to investigate target organ 
injury, if such an evaluation is not already available.6,29 
In particular, it would seem indefensible to proceed 
with anaesthesia in such patients without an ECG, at 
the very least, and some evaluation of renal function. 
Clinical history of effort tolerance is important in these 
patients, and may assist in guiding further evaluation. 
Stage 4 hypertension does appear to present a 
significant perioperative risk, and such patients 
should be deferred for treatment if at all possible. A 
suggested algorithm for decision making is presented 
in Figure 1. All hypertensive patients should be 
investigated for target organ damage, but this may 
take place following surgery in asymptomatic patients 
with Stage 1 or 2 hypertension.
If the decision is made to delay surgery, the anaesthetist 
is obliged to advise the surgeon on how to best manage 
the patient. If the patient is already on antihypertensive 
medication, but is poorly responsive, simply increasing 
the dosage of currently prescribed drugs would 
seem to be an inadequate approach. Rather, in 
consultation with a physician, a change in therapy 
to beta blockade, calciumchannel antagonists or an 
ACE inhibitor is probably more appropriate. However, 
such a change in therapy will require re-evaluation of 
end-organ status. The untreated hypertensive appears 
to present less of a risk than the poor responder to 
therapy, unless the hypertension is Stage 4.
There seems little logic to the concept of rapid, 
overnight reduction in blood pressure, as such a 
strategy will probably increase the risk of intraoperative 
haemodynamic instability. Again, if surgery can be 
delayed, a combined approach with the physician 
is appropriate, and in the severe hypertensive, 
consideration should be given to the use of agents 
such as beta blockers, calcium-channel antagonists 
or ACE inhibitors, which can favourably remodel 
the cardiac and vascular structures, together with 
statins for those with high cardiac risk. It is important 
that the anaesthetist emphasises the importance of 
following up the patient properly prior to reassessment 
for anaesthesia and surgery to surgical colleagues. 
In a recent retrospective study, increasing severity of 
pre-induction hypertension was an independent risk 
factor for postoperative myocardial injury/infarction or 
in-hospital death. However, only a small percentage 
of operations for patients presenting with severe 
hypertension was postponed, and the surgery delay did 
not result in interval normalisation of blood pressure,30 
indicating that inadequate follow-up of the postponed 
cases was conducted.
Once a hypertensive patient is accepted for 
anaesthesia, consideration must be given to the effects 
that the prescribed drugs may have on the anaesthesia. 
Withdrawal of antihypertensive medication is generally 
considered inadvisable, as many of these drugs may 
produce severe rebound effects when withdrawn. This 
applies to alphamethyldopa and clonidine particularly, 
Hypertension Asymptomatic 
SBP < 180 
Proceed to surgery 
SBP  > 180 
or PP > 80 
Routine investigations in all cases including 












Proceed to surgery 
Appropriate anaesthetic 





Figure 1: Algorithm for the approach to a patient with previously undiagnosed hypertension, presenting for anaesthesia and surgery.
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where severe hypertension may follow withdrawal. 
Withdrawal of beta blockers may precipitate angina. In 
the case of diuretics, the effects on renal function and 
electrolyte abnormalities must always be considered. 
The ACE inhibitors/ARBs represent a special case, 
and withdrawal of these agents 10 hours prior to 
surgery appears to be associated with a reduction in 
the risk of immediate post-induction hypotension.31 
Intraoperatively, haemodynamic stability appears 
to be more important than absolute values of the 
blood pressure.15 Controlling the intubation response 
is important, and a variety of agents (including short-
acting opiates, glyceryl trinitrate and magnesium 
sulphate) can be considered for this purpose, but the 
risks of post-induction hypotension must be borne in 
mind. Intraoperatively, esmolol, where available, may 
be very valuable for controlling sudden tachycardia 
and hypertension, but it must be remembered that 
beta blockade is contraindicated if the hypertensive 
event is due to an excess of catecholamines, caused 
either by administration of adrenaline or cocaine 
by the surgeon, or by endogenous secretion (e.g. 
phaeochromocytoma). In these latter circumstances, 
MgSO4, as a 4-g bolus, is probably the safest and most 
effective first-line therapy, and should constitute routine 
initial treatment of any intraoperative hypertensive 
crisis. Alpha2-agonists, as part of the anaesthetic 
technique, may provide useful blood pressure control, 
together with enhanced analgesia, and some 
protection against myocardial ischaemia.32 There is 
some evidence that volatile anaesthesia, in particular 
with sevoflurane, may be beneficial in that it may 
improve diastolic function,33 and provide some degree 
of ischaemic preconditioning.34 Postoperatively, care 
must be taken to ensure that a hypertensive crisis 
does not ensue, and that good analgesia is instituted. 
A strategy must be developed for blood pressure 
control, including a planned early return to standard 
preoperative therapy.
Conclusion
In conclusion, the following quotation best 
describes the current status of our understanding 
of hypertension and the indications for cancelling 
surgery: “Modern anaesthesia provided by a well-
trained, experienced and dedicated anaesthetist 
offers sufficient perioperative cardiac protection to 
make cancellation of surgery for the sole purpose of 
controlling preoperative hypertension unnecessary 
under most circumstances”.21
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